Purchase this article with an account.
Takahiro Suzuki, Kenji Kawai; The Effects of Topical Dorzolamide on preventing Macular Edema after vitrectomy via anti-inflammatory. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2605.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To prospectively evaluate the efficacy of a topical carbonic anhydrase inhibitor on macular edema after vitrectomy.
20 patients after vitrectomy for epiretinal membranes were included in this prospective trial. 10 eyes of 20 patients received topical 2% dorzolamide, three times a day. The patients were followed-up for 3 months at least. In this study, the effect of dorzolamide on visual acuity (VA), intraocular pressure, central macular thickness (CMT), and aqueous flare was evaluated.
Mean VA at the preoperation, and 2weeks, 1 and 3 months after operation between the treatment group (0.33 (20/60.6), 0.25 (20/80), 0.40 (20/50), and 0.58 (20/34.5) ) and the control group (0.4 (20/50), 0.36 (20/55.6), 0.48 (20/41.7), and 0.68 (20/29.4) ) were not statistically significant. Mean CMT at the preoperation, 2weeks and 3 months after operation, and mean aqueous flare at the operation, and 1 and 3 months between the treatment group (572.6, 427.2, and 333.4μm: 8.6, 34.2, and 23.5ph/ms) and the control group (571.4, 485.2, and 388.4μm: 9.7, 24.7, and 23.4ph/ms) were not statistically significant. But mean CMT at 1 month and mean aqueous flare at 2weeks after operation between the treatment group (358.8μm, 36.8ph/ms) and the control group (467.8μm, 64.0 ph/ms) were statistically significant (p<0.05). Mean intraocular pressure at the preoperation, and at 2weeks, 1 and 3 months after operation between the treatment group and the control group were not statistically significant, and intraocular pressure never exceeded 21mmHg.
Topical dorzolamide significantly reduced mean CMT at 1 month after operation for epiretinal membranes compared with control. Although further investigation on more cases and longer follow-up are needed, this study suggests that a topical dorzolamide can be efficacious in reducing macular edema in the early phase of post-vitrectomy via anti-inflammatory.
This PDF is available to Subscribers Only